Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Our management team has the experience, expertise and passion to translate the promise of our Fleximer platform into therapies that make a dramatic difference for patients. They bring to bear deep expertise in the critical disciplines of biology, chemistry, polymer science, drug development and oncology, and the collaborative leadership style needed to build a company of exceptional value.